Civil litigation firm Pope McGlamry is proud to announce that shareholder Mike McGlamry has been appointed as Co-Lead Counsel for the Plaintiffs in In Re: Zantac (Ranitidine) Products Liability Litigation, Multi-District Litigation (MDL) No. 2924, by the Honorable Robin L. Rosenberg.
McGlamry will serve as Co-Lead Counsel alongside Bobby Gilbert (Kopelowitz Ostrow Ferguson Weiselberg Gilbert), Tracy Finken (Anapol Weiss), and Adam Pulaski (Pulaski Kherkher).
Pope McGlamry Is An Early Leader in the Zantac Lawsuit
Prior to his appointment as Co-Lead, Judge Rosenberg appointed McGlamry to serve on the Initial Census Team to design and implement an initial census and registry process. While gathering data through an initial census has become a trend in recent MDLs, the census and registry process Judge Rosenberg has implemented in this litigation is unprecedented, and one both Plaintiffs and Defendants believe will be of great benefit.
McGlamry was also appointed to the April Deliverables Team, where he was responsible for filings and submissions, discovery efforts, and continued implementation of the census on behalf of the Plaintiffs. Pope McGlamry attorneys Kirk Pope, Courtney Mohammadi, and Caroline McGlamry will be assisting Mike with the Zantac litigation.
About the Zantac Cancer Lawsuit
Zantac/Ranitidine is an antacid and antihistamine that was commonly used to treat and prevent heartburn, as well as stomach ulcers, gastroesophageal reflux disease (GERD), and other conditions that cause excess stomach acid. On April 1, 2020, the Food and Drug Administration (FDA) issued a recall requesting that all manufacturers immediately withdraw prescription and over-the-counter (OTC) Zantac/Ranitidine products due to excess levels of NDMA, a probable human carcinogen in the drug. The FDA noted that its ongoing investigation of Zantac/Ranitidine determined that levels of NDMA increase over time and when the drug is stored at higher-than-normal temperatures. Consumers have been advised to stop taking any Zantac/Ranitidine tablets or liquid medications.
The Zantac MDL is based in the United States District Court for the Southern District of Florida. It will join defective drug liability cases from all over the country against the makers and distributors of Zantac, including GlaxoSmithKline, Pfizer, Boehringer Ingelheim, and Sanofi. Cases in the MDL seek to provide compensation for individuals that have developed cancer as a result of taking Zantac or Ranitidine.
